Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy

FDA meeting minutes confirm the previously disclosed End-of-Phase 2 outcomes and add further detail on the planned Phase 3 protocol. The update is largely procedural/confirmatory with no new efficacy/safety metrics or guidance, implying limited near-term repricing risk/benefit for the program.

Analysis

FDA meeting minutes confirm the previously disclosed End-of-Phase 2 outcomes and add further detail on the planned Phase 3 protocol. The update is largely procedural/confirmatory with no new efficacy/safety metrics or guidance, implying limited near-term repricing risk/benefit for the program.